ALKS Overview
Upcoming Projects (ALKS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ALKS)
-
Examining Alkermes' ALKS 2680 in treating Narcolepsy Type 2 and Idiopathic Hypersomnia
Ticker: ALKS
Executed On: Apr 26, 2024 at 02:00 PM EDT -
A Second Opinion: Interpreting both Alkermes’ ALKS-2680 and Takeda’s TAK-861 initial data for narcolepsy and how the OX2R class may ultimately fit in the treatment paradigm
Tickers: ALKS, TAK, CNTA
Executed On: Dec 08, 2023 at 09:30 AM EST -
Interpreting both Alkermes’ ALKS-2680 and Takeda’s TAK-861 initial data for narcolepsy and how the OX2R class may ultimately fit in the treatment paradigm
Tickers: ALKS, TAK, CNTA
Executed On: Nov 27, 2023 at 01:30 PM EST
Expired Projects (ALKS)
-
After ALKS Shows That the Third Time Really Can Be the Charm, Let's discuss the data and Kappa Opioid Receptor Antagonist Class 5
Tickers: CERC, ALKS
Execute By: Dec 14, 2016
Upcoming & Overdue Catalysts (ALKS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ALKS)
-
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar Disorder
Ticker: ALKS
Occurred on: Oct 09, 2020 -
Alkermes ALKS 8700 for the treatment of multiple sclerosis expected to submit NDA in 2018
Ticker: ALKS
Occurred on: Dec 17, 2018 -
ALKS study of ALKS 3831 on olanzapine associated weight gain related to schizophrenia expected to complete in the first half of 2018
Ticker: ALKS
Occurred on: Apr 26, 2018 -
Alkermes (ALKS) Phase 1 Study Testing ALKS-4230, on Solid Tumors Expected late 2017
Ticker: ALKS
Occurred on: Nov 08, 2017 -
Data for Alkermes' ALKS-3831 human metabolic study for schizophrenia due mid-2017
Ticker: ALKS
Occurred on: Jun 29, 2017 -
PDUFA Date of June 5th for Alkermes' (ALKS) sNDA for Two-Month Dosing of Aristada in Treatment of Schizophrenia
Ticker: ALKS
Occurred on: Jun 06, 2017 -
Alkermes ARISTADA, which treats patients with schizophrenia, seeking FDA approval for two-month dose in 2017
Ticker: ALKS
Occurred on: Mar 20, 2017 -
FORWARD-5 data read out for ALKS-5461 in Treatment Resistant Depression (TRD), the 3rd of 3 Phase 3 trials currently underway
Ticker: ALKS
Occurred on: Oct 21, 2016 -
Alkermes (ALKS) Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia
Ticker: ALKS
Occurred on: Oct 03, 2016 -
Alkermes Initiates Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119; Results are expected in the second half of 2016
Ticker: ALKS
Occurred on: Jul 14, 2016 -
Phase 3 data for third trial of ALKS 5461 due mid-2016
Ticker: ALKS
Occurred on: May 24, 2016 -
Phase 3 data from first two trials of ALKS 5461 for Major depressive disorder due 1Q 2016
Ticker: ALKS
Occurred on: Jan 21, 2016 -
FORWARD-3 data read out for ALKS-5461 in Treatment Resistant Depression (TRD) the second of 3 Phase 3 trials currently underway
Ticker: ALKS
Occurred on: Jan 21, 2016 -
Data read out from ALKS 5461 FORWARD-4 trial in Treatment Resistant Depression the first of 3 Phase 3 trials currently underway
Ticker: ALKS
Occurred on: Jan 21, 2016 -
New patent(No. 9,193,685) issued for ARISTADA, Extending Protection Into 2033
Ticker: ALKS
Occurred on: Dec 16, 2015
Strategic Initiatives (ALKS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
